Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19 (MELCOVID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04568863|
Recruitment Status : Recruiting
First Posted : September 29, 2020
Last Update Posted : September 29, 2020
|Condition or disease||Intervention/treatment||Phase|
|COVID-19 SARS-CoV 2 Coronavirus Infection||Drug: Melatonin intravenous Drug: Placebo intravenous||Phase 2|
ICU COVID-19 patients show high risk of death mainly due to sepsis and respiratory disfunction. Prevention of these critical conditions is mandatory to reduce mortality and to improve patient's outcome.
Melatonin is an endogenous hormone involved not only in circadian rhythm control, but also in the cell protection due to its outstanding anti-inflammatory and antioxidative effects. High doses of melatonin have shown high efficacy against bacterial (sepsis) and viral infections. Melatonin is a safe product that consistently has shown lack of side-effects when it is administered to humans.
SARS-CoV 2 infection may yield severe forms of the disease that require the patients admission to the ICU. These patients may develop an excessive inflammatory response and a burst of free radicals, constituting the major cause of death in these subjects.
Our hypothesis is that high doses of melatonin intravenously administered to COVID-19 ICU patients might reach enough blood levels able to prevent/counteract the developing of sepsis and the production of free radicals, reducing mortality and hospital stay.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||18 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||phase II, single-center, double-blind, randomized placebo-controlled trial|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)|
|Actual Study Start Date :||June 20, 2020|
|Estimated Primary Completion Date :||October 30, 2020|
|Estimated Study Completion Date :||November 30, 2020|
(12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
Drug: Melatonin intravenous
7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
Placebo Comparator: Placebo
(6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
Drug: Placebo intravenous
7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
- Mortality [ Time Frame: one month ]Mortality in each study group represented in frequency and time-to-event at day 28 after randomization
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04568863
|Contact: Germaine Escames, PhD||+34950241000 ext email@example.com|
|Hospital Universitario La Paz||Recruiting|
|Madrid, Spain, 28046|
|Contact: Germaine Escames, PhD +34958241000 ext 20363 firstname.lastname@example.org|
|Contact: Darío Acuña-Castroviejo, PhD +34958241000 ext 20169 email@example.com|
|Principal Investigator: Juan C Figueira, PhD|
|Sub-Investigator: Pedro C de la Oliva, PhD|
|Sub-Investigator: Cristina Arévalo Martín, PhD|
|Sub-Investigator: Claudio Gutiérrez Mavarez, PhD|
|Sub-Investigator: Andoni García Muñoz, PhD|
|Sub-Investigator: Alberto Borovia, PhD|
|Sub-Investigator: Irene García García, PhD|
|Sub-Investigator: Miguel Rodríguez Rubio, PhD|
|Sub-Investigator: José M Añón, PhD|
|Sub-Investigator: José R Arribas, PhD|
|Sub-Investigator: Julio García Rodríguez, PhD|
|Sub-Investigator: Darío Acuña-Castroviejo, PhD|
|Sub-Investigator: Germaine Escames, PhD|